Power Law company profile

Eikon Therapeutics

Biotech & Life Sciences · Hayward, United States · Founded 2019 · IPO 2026 Unicorn

Pioneering a new method of drug discovery based on tracking and measuring movement of individual proteins in live cells

Valuation

$333M

Market cap · May/2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

23 investors on Eikon Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage

Lux Capital

Series A 3 investors entered at this stage

Innovation Endeavors

Foresite Capital

The Column Group

Series B+ 19 investors entered at this stage

Hartford HealthCare Endowment

AME Cloud Ventures

Alexandria Venture Investments

E15 VC

EcoR1 Capital

Janelia

Schroders

T. Rowe Price

University of California

Berkeley

CPP Investments

Soros Capital Management

Horizons Ventures

UC Investments

Abu Dhabi Investment Authority

Harel Group

StepStone Group

General Catalyst

Soros Fund Management

Ownership

Who owns Eikon Therapeutics

Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (May/2026). Percentages are indicative.

34.6% Founders

Some investors are hidden on this public profile. See the full cap table on Dealroom →

Global footprint

Where Eikon Therapeutics has talent and traffic

Workforce by country

4 countries with
team presence

🇺🇸 United States99.3%

🇩🇰 Denmark0.3%

🇭🇰 Hong Kong0.3%

🇨🇦 Canada0.3%

4 countries shown

Web traffic by country

11K monthly visits
across markets

🇺🇸 United States87.3%

🇮🇳 India9.1%

🇬🇧 United Kingdom3.6%

🇩🇪 Germany0%

Top 4 markets shown

Talent graph

The shape of Eikon Therapeutics's talent

Dealroom maps Eikon Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

11 standout operatorsDealroom-flagged across the org

9 AI specialistsincl. 4 core researchers

404 employees mappedperson by person

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Eikon Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$35M patent portfolio · 56 active families

Estimated portfolio value

$35M

10.5% of market cap · 5.5× larger than top peer Freenome ($6M)

56 active patent families

Where Eikon Therapeutics innovates BioinformaticsComputational biologyDirect acyclic graphDirected acyclic graphComputer science

Where Eikon Therapeutics concentrates vs peers

Each axis is a top-10 topic across Eikon Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Eikon Therapeutics

An AI-synthesized read of the highest-engagement posts about Eikon Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Eikon Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles